Purpose: Severe oral and pharyngeal mucositis is one of the most critical toxicities known to lead to the discontinuation of chemoradiotherapy (CRT) for head and neck cancer (HNC). Hangeshashinto (TJ-14) is a Kampo medicine that relieves chemotherapy-induced oral mucositis. We investigated the effect of TJ-14 on mucositis, nutritional status, and the completion rate of CRT. Methods: The study group comprised patients with advanced HNC who were treated with concomitant weekly cisplatin and 70 Gy of radiotherapy. The primary endpoint was the completion rate of chemotherapy, and the secondary endpoints were the grade of mucositis and the nutritional status. Results: A total of 57 patients were included in this study. The completion rate of CRT among patients who were treated with TJ-14 was 91.4%. There was a significant difference in the completion rate of CRT between the groups treated with and without TJ-14 (p = 0.0452). The reduction in body weight was significantly improved from 10.89 to 5.89% with TJ-14 administration (p = 0.003), and the reduction in serum albumin was also significantly decreased from 17.37 to 8.73%. (p = 0.024). Conclusion: This therapy allowed a high completion rate of CRT as well as significant benefits in terms of nutritional status. We plan to carry out a further large-scale study of TJ-14.
Introduction
Concomitant chemotherapy with radiation for head and neck cancer (HNC) provides a favorable prognosis as well as a significantly higher rate of organ preservation in comparison with radiation alone [1, 2] . Radiation with high-dose cisplatin every 3 weeks remains the most standard regimen in clinical trials by US Cooperative Groups. However, the toxicity of this regimen is too severe for most Japanese patients to complete; therefore, our institute has introduced a regimen of radiation with weekly 40 mg/m 2 of cisplatin [3] . We have to date achieved good clinical outcomes with acceptable toxicity in terms of neutropenia and renal failure [4] . However, the completion rate of this regimen remains around 60% and severe oral and pharyngeal mucositis sometimes causes the discontinuation of chemoradiotherapy (CRT).
Hangeshashinto (TJ-14) is a Japanese traditional medicine (Kampo) that includes 7 natural extracts: Pinelliae tuber, Scutellariae radix, Zingiberis rhizoma, ginseng radix, Glycyrrhizae radix, Zizyphi fructus, and Coptidis rhizoma. TJ-14 has been reported to regulate prostaglandin E2 in in vivo colitis models and to reduce chemotherapy-induced severe oral mucositis in gastric cancer patients [5] [6] [7] . The degree of severity of oral and pharyngeal mucositis varies during CRT for pharyngeal cancer, and new agents are needed to improve completion rates and to limit pain in these patients
This study evaluates the effect of TJ-14 on the completion rate of CRT in patients with cancers of the oropharynx and hypopharynx through the regulation of CRT-induced oral and pharyngeal mucositis. This is the first trial to use TJ-14 as a gargle to prevent mucositis induced by chemoradiation. In this study we investigated the compliance of TJ-14 for CRT in oro-and hypopharyngeal cancer as well as the completion rate. Furthermore, nutritional status, grade of mucositis, and pain were estimated in comparison with patients treated without TJ-14.
Patients and Methods

Patients
The study group comprised Japanese patients who were diagnosed with advanced oropharyngeal and hypopharyngeal squamous cell carcinoma and treated with CRT at Hokkaido University Hospital, Sapporo, Japan. Written informed consent was obtained from all patients before entry into the study. This study was approved by the Institutional Review Board of Hokkaido University Hospital (UMIN000006461).
CRT and TJ-14 Administration
All patients were treated with a total dose of 70 Gy of radiation in 35 daily fractions. After the initial dose of 40 Gy had been administered, an additional dose of 30 Gy was given with a shrunken field in 15 fractions over 3 weeks. Weekly cisplatin was administered at a dose of 40 mg/m 2 on weeks 1, 2, 3, 4, 6, and 7 of radiation therapy. The intended maximum total dose of cisplatin was 240 mg/m 2 .
Patients received 2.5 g of TJ-14 as a gargle three times a day as follows: (1) 2.5 g of TJ-14 was dissolved in 40 ml of drinking water and patients rinsed the oral cavity and pharynx with the solution, without swallowing, for more than 5 s, (2) TJ-14 was expelled out after rinsing and was not to be swallowed, and (3) patients were advised not to consume any food or drink within 30 min after rinsing with TJ-14. CRT and TJ-14 administration schedules are shown in figure 1 .
Evaluation of Mucositis, Pain, and Nutritional Status
Oral and pharyngeal mucositis were graded as according to CTCAE v4.0. The maximum dose of morphine was defined as that on day 57. Body composition of all patients was estimated by bioelectric impedance analysis using an InBody S20 body composition analyzer with InBody 3.0 software (BioSpace) on days 0 and 57 [8] . Nutritional intake was assessed by the Nutrition Support Team of Hokkaido University Hospital by measuring the weight of each dish before and after every meal. Furthermore, the calories of all additional foods, snacks, and drinks were added to the measured food intake. Total oral intake of calories and protein were recorded as the average of 3 days in the 1st, 3rd, 6th, and 8th week. The serum levels of albumin, pre-albumin and retinolbinding protein were used as nutritional status markers and were estimated on days 1, 22, 43, and 57.
Statistical Considerations
The primary endpoint was the completion rate of CRT. Complete chemoradiation treatment delivery was defined as the administration of the full dose of 70 Gy radiation within 63 days, and the completion of at least 5 of 6 courses of cisplatin. Complete administration of TJ-14 was defined as more than 7 weeks of treatment without interruption. The secondary endpoints were oral and pharyngeal mucositis grade, nutritional status, and maximum morphine dose.
Results
Patient Characteristics
Demographic and clinicopathological data, including age, gender, tumor site, TNM stage, smoking, and alcohol abuse of all patients are shown in table 1 . In total, 23 patients with oropharyngeal cancer and 34 patients with hypopharyngeal cancer were included in this study. Forty patients had stage IV disease, 6 had stage III disease, and 10 had stage II. Of the 57 patients, 12 (11 male and 1 female) received TJ-14 treatment and were enrolled in the study and evaluated from January 2012 through September 2013. The other 45 patients were treated without TJ-14 from June 2006 through January 2011. The age range of the patients treated with TJ-14 was 40-70 years (median 60) and that of the patients treated without TJ-14 was 40-75 years (median 59). All patients received oral care during CRT from the Dental Care Team of Hokkaido University Hospital.
TJ-14 Compliance
Of the 12 patients, 9 completed 7 or 8 weeks of treatment with TJ-14. The other 3 patients could not continue to use TJ-14, but they completed the CRT. Of these, 1 patient discontinued TJ-14 on day 6 due to its bitter taste. One patient could not keep himself from eating or drinking for 30 min after gargling with TJ-14 and stopped the study on day 16. The third patient discontinued TJ-14 on day 38 due to vomiting and nausea. No patients interrupted TJ-14 treatment due to oral and pharyngeal mucositis.
CRT Completion Rate
The completion rate of CRT is summarized in table 2 . All patients who were treated with TJ-14 received the full dose of radiotherapy (RT; 70 Gy) without interruption. A total of 11 (91.6%) patients completed five (5 patients) or six (6 patients) courses of chemotherapy. One patient could not receive a 5th course of chemotherapy due to fever. Of the 9 patients who completed treatment with TJ-14, 8 (88.9%) also completed CRT. Of the 45 patients treated without TJ-14, 18 interrupted CRT. The causes of chemotherapy interruption were neutropenia in 4 cases, fever in 4, renal failure in 3, liver dysfunction in 1, mucositis in 1, tumor bleeding in 1, and rejection of CRT in 2 patients. The radiation course was extended in 2 cases by holidays and machine maintenance [9] . There was a significant difference in the completion rate of CRT between the groups with and without TJ-14 (p = 0.0452, Fisher's exact test).
Mucositis and Pain
There were no significant differences in the maximum grade of mucositis and the maximum dose of morphine between patients treated with and without TJ-14 ( The numbers shown in parentheses refer to the patients who completed the treatment with TJ-14. Table 2 . Completion rate of CRT 4 mucositis was absent. Whereas in the non-TJ-14-administered group, grade 3 mucositis was developed in 25 (57.8%) patients and grade 4 mucositis occurred in 1 patient. A significant difference was not observed in the mean maximum dose of morphine between grade 1-2 and grade 3-4 mucositis.
Body Composition Analysis and Nutritional Status
We investigated the body composition index of the patients treated with TJ-14 to reveal their nutritional status ( table 4 ). The median body weight of the patients was significantly decreased after chemoradiation (p = 0.006) with a median decrease in body weight of 5.89% (maximum 11.7%, minimum -2.8%). Median fat and bone mass did not change during CRT, but the muscle mass and total body water were significantly decreased by 5.7 and 5.5%, respectively (muscle mass: p = 0.045; body water: p = 0.049). The median metabolic rate also decreased by about 4.0% during CRT. Table 5 shows the changes in median oral intake of calories and nutritional status markers in the serum. The median total oral intake of calories drastically decreased after the 4th week of treatment. Seven patients had received percutaneous endoscopic gastrostomy (PEG) before CRT, and 4 of the 7 patients started to use PEG feeding due to oral feeding difficulties on days 21, 36, 45, and 47, respectively. The median level of albumin and pre-albumin in the serum gradually decreased throughout the course of CRT, but the changes were not statistically significant. The mean serum concentration of retinoid-binding protein increased in the 3rd week but decreased again after the 6th week
The median reduction in body weight during CRT without TJ-14 was 10.72%, and the reduction in serum albumin was 17.37%, whereas the reduction in body weight was significantly improved up to 5.89% with TJ-14 administration (p = 0.003) and serum albumin was also significantly decreased to 8.73% (p = 0.024; fig. 2 ). 
Discussion
Toxicities with CRT often lead to treatment interruptions that are invariably associated with a poorer outcome [10, 11] . To improve the completion rate of CRT for HNC, we modified the regimen and improved the management program in terms of the hydration protocol and the adequate administration of G-CSF to avoid severe leucopenia, neutropenia, and renal failure [4] . Although nausea and vomiting were one of the most severe side effects of cisplatin administration, it was dramatically improved with the administration of dexamethasone and serotonin 5-HT3 receptor antagonists [12] . On the other hand, the pain and dysphagia associated with severe oral and pharyngeal mucositis have been a critical factor in the completion rate. Most patients with oropharyngeal and hypopharyngeal cancer undergoing CRT receive direct irradiation to the oral cavity and pharynx, so it is easy to assume that therapy-induced mucositis is more severe than in other digestive cancers. Severe direct irradiation-induced mucositis led us to apply TJ-14 for oro-and hypopharyngeal cancers at first, with the gargle therapy involving TJ-14 achieving good compliance with a completion rate of 75%. Only 1 patient had an early interruption of treatment with TJ-14 due to its bitter taste, and no patient discontinued treatment due to oral mucositis or pain.
The pilot study of TJ-14 for chemotherapy-induced oral mucositis in gastric cancer showed a significant effect [13] . However, a double-blind, placebo-controlled, randomized phase II study of TJ-14 did not show any difference in the oral mucositis grade but a tendency for TJ-14 to reduce the duration of chemotherapy-induced oral mucositis from 17 to 9 days was observed. [7] We have previously reported that the rate of grade 3-4 mucositis induced by the same regimens of CRT for HNC was 39.6% [4] . If limited to oropharyngeal and hypopharyngeal cancers, the rate of grade 3-4 mucositis was 51.6% [9] . In this study, no patients had grade 4 mucositis, and the rate of grade 3 mucositis decreased to 41.6%. Unlike the study on gastric cancer, no statistical significant effect of TJ-14 in terms of mucositis grade could be observed. However, no patient interrupted CRT due to mucositis, and most of the grade 2-3 mucositis occurred in the late phase of CRT in the TJ-14-administered group. These facts might have induced the beneficial change in the completion rate of CRT and the nutritional status. No statistical differences in oral mucositis were observed because of the fuzzy grading system. The grading in oral mucositis of CTCAE v4.0 has only 5 grades and lacks clarity, and the real extent of mucositis was different in the same grade. Therefore, a more extensive method of mucositis evaluation than CTCAE v4.0 is needed. Molecular targeted therapy using cetuximab, an epidermal growth factor receptor monoclonal antibody, has recently been investigated in conjunction with radiation therapy for advanced HNC patients, and has shown promising results [14, 15] . Radiation therapy with cetuximab does not cause toxicity leading to leucopenia, neutropenia, or renal failure and is relatively safe compared to platinum-based CRT. However, severe mucositis occurs more often during radiation therapy with cetuximab, so a new agent to prevent radiation-induced mucositis is needed. TJ-14 may be a promising option for use in combination with cetuximab treatment for HNC.
One of the reasons for the improvement in the completion rate of CRT with TJ-14 is the good outcome in terms of nutritional status. Recently, several studies have suggested that early and intensive nutritional support improved the quality of life and outcome of HNC patients undergoing RT or CRT [16] [17] [18] [19] [20] . Capuano et al. [21] showed that a weight reduction of more than 20% significantly increased CRT-induced toxicity, risk of early mortality, and hospital readmission rate. To improve nutrition, we introduced oral care, a PEG feeding prior to treatment, and a pain management program based on the combined efforts of dentists and supportive care staff. Despite the introduction of a PEG feeding and oral care, the median reduction in body weight during CRT remained around 10%. It is interesting to note that most of the body weight loss involved the loss of body water and muscle mass, so that the control of dehydration and muscle maintenance may improve the nutritional status. Although this study was a single-arm trial and not a controlled randomized trial with a placebo, our results suggest that an improved nutritional status might contribute to a higher completion rate of CRT. TJ-14 has been known as an agent for enhancing digestive activity, and it was originally used for acute and chronic gastritis, heartburn, and diarrhea. Patients often swallowed TJ-14 after gargling, so the possibility that it had an effect on digestive activity cannot be totally excluded. The anti-inflammatory effect of TJ-14 has been explained by its direct regulation of PGE2 and COX-2, but the mechanism by which it enhances digestive activity remains to be clarified [5, 6] . The effects of Kampo drugs have been known historically and confirmed empirically, and their mechanisms have been gradually revealed both biologically and pharmacologically. One of the advantages of Kampo drugs is their limited side effects, and several Kampo drugs have been used for supportive treatment for various cancers [22] [23] [24] . Although most Kampo drugs are composed and used according to traditional strategies, we should accumulate the cases and provide clinical evidence for their effective utilization. Seven components are included in TJ-14 and these interact with each other. Therefore, to reveal the mechanism of TJ-14, we need to investigate not only the function of all components, but also their cross-reactions.
In conclusion, the feasibility of TJ-14 for HNC CRT-induced oral mucositis was confirmed. Treatment with TJ-14 was shown to benefit the completion rate of CRT as well as the nutri-
